Compare Kinross Gold Corporation (KGC) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Medtronic PLC — how do they compare? Kinross Gold Corporation trades at $23.37 (market cap $26.63B), while Medtronic PLC trades at $82.39 (market cap $106.61B). The key difference: Medtronic PLC is far larger — about 4× Kinross Gold Corporation's market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| KGC | MDT | |
|---|---|---|
Market Cap | $26.63B | $106.61B |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $105.35 |
52-Week Low | $15.42 | $73.75 |
Enterprise Value | $25.18B | $125.36B |
Dividend Yield | 0.64% | 3.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $22.65, up 0.35% with strong fundamentals including 35.99% net margin and 35.15% ROE. The stock shows bearish technical signals despite consistent earnings beats and analyst consensus of $37.20 price target. Recent cash flow growth from $259M in 2024 to $1.13B in 2025 supports dividend payments and exploration projects.
KGC presents value opportunity with P/E of 9.6x below industry averages, though technical weakness and gold price volatility pose risks. Production growth to 2.3M+ ounces by 2028 and net cash position provide upside catalysts if gold prices stabilize.
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
